Literature DB >> 28741053

Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of 18FDG-PET/CT according to ΔSUVmax, Deauville 5-point scale and IHP criteria.

Emine Göknur Isik1, Serkan Kuyumcu2, Rejin Kebudi3, Yasemin Sanli1, Zeynep Karakas4, Fatma Betul Cakir4, Seher Nilgün Unal1.   

Abstract

OBJECTIVE: Minimizing side effects by using response-adopted therapy strategies plays an important role in the management of pediatric Hodgkin lymphoma (HL); however, the criteria for the definition of adequate or inadequate response are controversial. The aim of this study is to compare different methods of interpretation of 18F-FDG-PET/CT (PET) in the prediction of disease outcome in order to determine the optimum method in this regard.
METHODS: Baseline, interim and post-treatment PET scans of 72 children were interpreted according to revised International Harmonization Project criteria (IHP) and Deauville criteria. Cut-off values for changes in interim and post-treatment FDG uptake (ΔSUVmax) in the prediction of progression-free survival (PFS) were measured using ROC analysis. Quantitative and visual data were compared with each other in the prediction of PFS.
RESULTS: Mean interim and post-treatment ΔSUVmax of the primary lesions were 77.4 ± 19.5 and 68.8 ± 30.4% and respective cut-off values were 82 and 73%. However, only post-treatment ΔSUVmax yielded statistically significant results in the prediction of 3-year PFS (p = 0.043). Interim ΔSUVmax was further analyzed according to the values reported in the literature (66 and 77%) yet statistically significant results were not reached (p = 0.604 and 0.431). For interim evaluation, IHP criteria was correlated to Deauville criteria (p = 0.002 and p = 0.001) and ΔSUVmax (p = 0.03), whereas for post-treatment evaluation, significant correlation with ΔSUVmax (p = 0.04) but marginally significant (p = 0.055 and p = 0.058) correlation with Deauville criteria were achieved. Overall, 1, 3 and 5-year PFS were 95.7 ± 0.2, 89.6 ± 0.4 and 80.8 ± 0.7%, respectively. All methods demonstrated comparable performance in the prediction of 3-year PFS; however, interim PET using Deauville criteria and post-treatment PET using IHP criteria were statistically significant. All methods demonstrated high negative-predictive value but substantially low positive-predictive value.
CONCLUSIONS: Deauville criteria are superior to other methods in the prediction of pediatric HL outcome using interim PET data. On the other hand, quantitative evaluation and visual evaluation by IHP can be used reliably at the end of the treatment. In this regard, we report the optimal cut-off value of SUVmax reduction as 73%.

Entities:  

Keywords:  Deauville; FDG-PET/CT; IHP criteria; Pediatric Hodgkin lymphoma

Mesh:

Substances:

Year:  2017        PMID: 28741053     DOI: 10.1007/s12149-017-1196-x

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  4 in total

Review 1.  PET/CT Evaluation of the Effect of Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of T-Cell Lymphoblastic Lymphoma.

Authors:  Jin Zhao; Xiaojing Guo; Li Ma; Meijing Zheng; Tao Guan; Liping Su
Journal:  Contrast Media Mol Imaging       Date:  2022-08-16       Impact factor: 3.009

Review 2.  RESISTing the Need to Quantify: Putting Qualitative FDG-PET/CT Tumor Response Assessment Criteria into Daily Practice.

Authors:  J G Peacock; C T Christensen; K P Banks
Journal:  AJNR Am J Neuroradiol       Date:  2019-11-28       Impact factor: 4.966

3.  Early Radiation-Induced Sarcoma in an Adolescent Treated for Relapsed Hodgkin Lymphoma with Nivolumab.

Authors:  Lukas Šalaševičius; Goda Elizabeta Vaitkevičienė; Ramunė Pasaulienė; Rosita Kiudelienė; Ernesta Ivanauskaitė-Didžiokienė; Donatas Vajauskas; Nemira Jurkienė; Jelena Rascon
Journal:  Medicina (Kaunas)       Date:  2020-03-31       Impact factor: 2.430

4.  The Utility of Metabolic Parameters on Baseline F-18 FDG PET/CT in Predicting Treatment Response and Survival in Paediatric and Adolescent Hodgkin Lymphoma.

Authors:  Janet Denise Reed; Andries Masenge; Ane Buchner; Fareed Omar; David Reynders; Mariza Vorster; Christophe Van de Wiele; Mike Sathekge
Journal:  J Clin Med       Date:  2021-12-20       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.